Skip to main content
Psychedex

1Provenance card

the boundary, as counts

Sources

3022 with DOI

9 strong · 12 moderate · 9 weak

Compilations

12026-05-11T15:15:28.135Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

31last ruled 2026-06-04

0 awaiting a ruling

Issued documents

52026-10-19T20:30:17.238Z

notice · info card · emergency

Searches

131 with no results

queries and counts on the build

Claims checked

9265 supported

65 supported · 27 not

Correspondence

0received

consent field ships in Phase 4

Edges

273

derivations recorded for this entity

Complete over 30 sources, 1 compilation, and 31 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/5f-akb48/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued emergency
  2. 2026-10-19issueIssued info_card
  3. 2026-09-07srcScreening, quantification, and confirmation of synthetic cannabinoid metabolites in urine by UHPLC-QTOF-MS.
  4. 2026-09-07srcDetection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market.
  5. 2026-09-07srcNew drugs of abuse.
  6. 2026-09-07srcSynthetic Cannabinoid-Associated Multiple Organ Failure: Case Series and Literature Review.
  7. 2026-09-07srcPharmacological evaluation of synthetic cannabinoids identified as constituents of spice.
  8. 2026-09-07srcSynthetic cannabinoid hyperemesis resulting in rhabdomyolysis and acute renal failure.
  9. 2026-09-07srcNoncanonical pharmacological inhibition of the hERG K+ channel by a synthetic cannabinoid.
  10. 2026-09-07src5F-AKB48: A synthetic cannabinoid presenting an emerging public health concern in France.
  11. 2026-09-07srcConcentrations of APINACA, 5F-APINACA, UR-144 and its degradant product in blood samples from six impaired drivers compared to previous reported concentrations of other synthetic cannabinoids.
  12. 2026-09-07srcMetabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity.
  13. 2026-09-07srcClinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020.
  14. 2026-09-07srcIdentification of AKB-48 and 5F-AKB-48 Metabolites in Authentic Human Urine Samples Using Human Liver Microsomes and Time of Flight Mass Spectrometry.
  15. 2026-09-07srcSynthetic Cannabinoids.
  16. 2026-09-07src"Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans
  17. 2026-09-07srcNovel psychoactive substances: types, mechanisms of action, and effects
  18. 2026-09-07srcThe synthetic cannabinoids menace: a review of health risks and toxicity.
  19. 2026-09-07srcFirst characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry.
  20. 2026-09-07srcClinical and analytical experience of the National Poison Control Centre with synthetic cannabinoids.
  21. 2026-09-07srcA systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment
  22. 2026-09-07srcEnantiospecific Synthesis, Chiral Separation, and Biological Activity of Four Indazole-3-Carboxamide-Type Synthetic Cannabinoid Receptor Agonists and Their Detection in Seized Drug Samples
  23. 2026-09-07srcSimilar 5F-APINACA Metabolism between CD-1 Mouse and Human Liver Microsomes Involves Different P450 Cytochromes.
  24. 2026-09-07srcSignificance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics.
  25. 2026-09-07srcSchedules of Controlled Substances: Placement of UR-144, XLR11, and AKB48 into Schedule I. Final rule.
  26. 2026-09-07srcAcute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
  27. 2026-09-07srcEffect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on 'tetrad', sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.
  28. 2026-09-07srcSchedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) Into Schedule I. Notice of Intent.
  29. 2026-09-07srcExtension of Temporary Placement of 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA in Schedule I
  30. 2026-09-07srcSchedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) Into Schedule I
  31. 2026-09-07src5F-APINACA substance details
  32. 2026-09-07src5F-APINACA (5F-AKB-48) Review Report, Expert Committee on Drug Dependence 38th and 42nd Meetings
  33. 2026-09-04issueIssued emergency
  34. 2026-09-04issueIssued info_card
  35. 2026-09-04issueIssued notice
  36. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  37. 2026-06-04publicationPublication — backfill
  38. 2026-05-11revisionRevision 1
  39. 2026-05-11absenceSearched ClinicalTrials.gov for "5F-AKB48 synthetic cannabinoid" — no results
  40. 2026-05-11genGeneration — pipeline-v5 · with 3 morepipeline-v5
  41. 2026-05-11rungeneration run

The same entries, as forms: six forms.